Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy, Intensity-Modulated | 9 | 2023 | 806 | 1.790 |
Why?
|
Oropharyngeal Neoplasms | 8 | 2023 | 475 | 1.730 |
Why?
|
Head and Neck Neoplasms | 13 | 2023 | 2712 | 1.510 |
Why?
|
Radiation Oncology | 3 | 2023 | 554 | 1.240 |
Why?
|
Paranasal Sinus Neoplasms | 8 | 2016 | 234 | 1.110 |
Why?
|
Carcinoma, Adenoid Cystic | 4 | 2016 | 252 | 1.040 |
Why?
|
Skull Base | 2 | 2016 | 299 | 0.820 |
Why?
|
Relative Biological Effectiveness | 2 | 2021 | 323 | 0.810 |
Why?
|
Radiotherapy Dosage | 13 | 2023 | 2876 | 0.760 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2023 | 4029 | 0.760 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2018 | 285 | 0.670 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2019 | 44 | 0.660 |
Why?
|
Diagnostic Techniques, Ophthalmological | 3 | 2006 | 246 | 0.660 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2021 | 1622 | 0.660 |
Why?
|
Skull Base Neoplasms | 3 | 2012 | 284 | 0.610 |
Why?
|
Visual Perception | 3 | 2015 | 1417 | 0.610 |
Why?
|
Nose Neoplasms | 3 | 2016 | 245 | 0.580 |
Why?
|
Radiotherapy | 4 | 2018 | 1525 | 0.560 |
Why?
|
Papillomavirus Infections | 6 | 2023 | 1585 | 0.480 |
Why?
|
Macula Lutea | 2 | 2006 | 151 | 0.480 |
Why?
|
Tomography, Optical Coherence | 4 | 2006 | 2637 | 0.440 |
Why?
|
Osteoradionecrosis | 1 | 2012 | 49 | 0.430 |
Why?
|
Touch | 1 | 2015 | 306 | 0.430 |
Why?
|
Sphenoid Sinus | 2 | 2009 | 100 | 0.410 |
Why?
|
Cutaneous Fistula | 1 | 2012 | 78 | 0.400 |
Why?
|
Neoplasm Metastasis | 5 | 2019 | 4839 | 0.400 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2012 | 140 | 0.400 |
Why?
|
Paranasal Sinus Diseases | 1 | 2012 | 116 | 0.390 |
Why?
|
Somatosensory Cortex | 1 | 2015 | 527 | 0.380 |
Why?
|
Carcinoma | 4 | 2018 | 2374 | 0.370 |
Why?
|
Fistula | 1 | 2012 | 218 | 0.360 |
Why?
|
Parietal Lobe | 1 | 2015 | 837 | 0.350 |
Why?
|
Deglutition Disorders | 2 | 2013 | 604 | 0.340 |
Why?
|
Cerebellar Neoplasms | 1 | 2012 | 585 | 0.300 |
Why?
|
Retina | 3 | 2013 | 2611 | 0.300 |
Why?
|
Medulloblastoma | 1 | 2012 | 681 | 0.290 |
Why?
|
Enteral Nutrition | 1 | 2013 | 763 | 0.290 |
Why?
|
Canthaxanthin | 1 | 2006 | 3 | 0.280 |
Why?
|
Papillomaviridae | 6 | 2022 | 1118 | 0.280 |
Why?
|
Disease-Free Survival | 8 | 2017 | 6891 | 0.280 |
Why?
|
Pyrroles | 1 | 2012 | 1143 | 0.260 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2038 | 0.250 |
Why?
|
Human Body | 1 | 2004 | 39 | 0.250 |
Why?
|
Extremities | 1 | 2010 | 865 | 0.240 |
Why?
|
Neuroma, Acoustic | 2 | 2005 | 450 | 0.240 |
Why?
|
Face | 1 | 2010 | 993 | 0.230 |
Why?
|
Indoles | 1 | 2012 | 1834 | 0.230 |
Why?
|
Photic Stimulation | 1 | 2010 | 2027 | 0.230 |
Why?
|
Retinal Perforations | 1 | 2004 | 131 | 0.220 |
Why?
|
Stereotaxic Techniques | 1 | 2005 | 535 | 0.220 |
Why?
|
Visual Fields | 1 | 2010 | 1049 | 0.220 |
Why?
|
Urea | 1 | 2004 | 449 | 0.210 |
Why?
|
Middle Aged | 31 | 2023 | 213127 | 0.210 |
Why?
|
Visual Cortex | 1 | 2010 | 1149 | 0.200 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 74 | 0.200 |
Why?
|
Macular Edema | 1 | 2005 | 359 | 0.190 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2022 | 104 | 0.190 |
Why?
|
Brain Mapping | 2 | 2015 | 6669 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2018 | 9185 | 0.190 |
Why?
|
Adult | 25 | 2021 | 213712 | 0.190 |
Why?
|
Neurofibromin 2 | 3 | 2012 | 267 | 0.190 |
Why?
|
Gastrostomy | 2 | 2013 | 309 | 0.190 |
Why?
|
Aged | 24 | 2023 | 162944 | 0.180 |
Why?
|
Male | 32 | 2023 | 349538 | 0.180 |
Why?
|
Radiation Injuries | 2 | 2018 | 1178 | 0.180 |
Why?
|
Retinal Diseases | 1 | 2006 | 683 | 0.180 |
Why?
|
Humans | 48 | 2023 | 742088 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2013 | 3471 | 0.170 |
Why?
|
Female | 31 | 2023 | 379592 | 0.170 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 13655 | 0.170 |
Why?
|
Smoking | 2 | 2016 | 8969 | 0.170 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 221 | 0.170 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2274 | 0.160 |
Why?
|
Radiosurgery | 2 | 2005 | 1309 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6534 | 0.160 |
Why?
|
Treatment Outcome | 11 | 2021 | 62966 | 0.160 |
Why?
|
Paranasal Sinuses | 2 | 2012 | 249 | 0.160 |
Why?
|
Brain | 2 | 2021 | 26343 | 0.160 |
Why?
|
Antioxidants | 1 | 2006 | 1659 | 0.160 |
Why?
|
Prognosis | 9 | 2023 | 29010 | 0.150 |
Why?
|
Nasal Cavity | 3 | 2012 | 312 | 0.150 |
Why?
|
Tracheotomy | 1 | 2018 | 166 | 0.150 |
Why?
|
Retrospective Studies | 17 | 2023 | 77098 | 0.150 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39004 | 0.140 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 173 | 0.140 |
Why?
|
Lymphatic Irradiation | 1 | 2016 | 104 | 0.130 |
Why?
|
Survival Rate | 5 | 2016 | 12773 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2017 | 57683 | 0.130 |
Why?
|
Monte Carlo Method | 1 | 2021 | 1254 | 0.130 |
Why?
|
Neurilemmoma | 2 | 2012 | 547 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 577 | 0.130 |
Why?
|
Neoplasm Staging | 6 | 2023 | 11001 | 0.130 |
Why?
|
Tumor Burden | 1 | 2021 | 1905 | 0.130 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 552 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2013 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 401 | 0.120 |
Why?
|
Laryngeal Neoplasms | 1 | 2018 | 512 | 0.120 |
Why?
|
Uncertainty | 1 | 2019 | 725 | 0.120 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2014 | 40 | 0.120 |
Why?
|
Protons | 3 | 2009 | 1126 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 21596 | 0.110 |
Why?
|
Physical Stimulation | 1 | 2015 | 525 | 0.110 |
Why?
|
Radiometry | 1 | 2018 | 800 | 0.110 |
Why?
|
Xerostomia | 1 | 2013 | 95 | 0.110 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12344 | 0.110 |
Why?
|
Neuroectodermal Tumors | 1 | 2012 | 27 | 0.110 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 376 | 0.100 |
Why?
|
Fingers | 1 | 2015 | 514 | 0.100 |
Why?
|
Esophageal Stenosis | 1 | 2013 | 194 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2017 | 934 | 0.100 |
Why?
|
Neck Dissection | 1 | 2013 | 196 | 0.100 |
Why?
|
Postoperative Complications | 2 | 2012 | 15244 | 0.100 |
Why?
|
Vision, Ocular | 1 | 2015 | 463 | 0.100 |
Why?
|
Nutritional Support | 1 | 2013 | 168 | 0.100 |
Why?
|
Young Adult | 6 | 2018 | 56350 | 0.100 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2012 | 236 | 0.090 |
Why?
|
Narcotics | 1 | 2013 | 343 | 0.090 |
Why?
|
Etoposide | 1 | 2012 | 637 | 0.090 |
Why?
|
Cranial Fossa, Anterior | 1 | 2009 | 13 | 0.090 |
Why?
|
Deglutition | 1 | 2011 | 197 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2012 | 6365 | 0.090 |
Why?
|
Oropharynx | 1 | 2009 | 127 | 0.080 |
Why?
|
Wnt Proteins | 1 | 2013 | 721 | 0.080 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 1095 | 0.080 |
Why?
|
Lacrimal Apparatus | 1 | 2010 | 224 | 0.080 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2007 | 79 | 0.080 |
Why?
|
Eye Neoplasms | 1 | 2010 | 313 | 0.080 |
Why?
|
Neuroglia | 1 | 2013 | 925 | 0.070 |
Why?
|
Models, Statistical | 2 | 2019 | 5100 | 0.070 |
Why?
|
Neutrons | 1 | 2006 | 76 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2012 | 1769 | 0.070 |
Why?
|
Gene Expression | 1 | 2019 | 7790 | 0.070 |
Why?
|
Cranial Fossa, Posterior | 1 | 2006 | 139 | 0.070 |
Why?
|
Cisplatin | 1 | 2012 | 1637 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3612 | 0.070 |
Why?
|
Cavernous Sinus | 1 | 2006 | 125 | 0.070 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2009 | 325 | 0.070 |
Why?
|
Body Weights and Measures | 1 | 2006 | 211 | 0.070 |
Why?
|
Survival Analysis | 3 | 2014 | 10248 | 0.060 |
Why?
|
Time Factors | 4 | 2017 | 40054 | 0.060 |
Why?
|
Triamcinolone Acetonide | 1 | 2005 | 101 | 0.060 |
Why?
|
Risk Factors | 5 | 2017 | 72145 | 0.060 |
Why?
|
Adolescent | 5 | 2018 | 85649 | 0.060 |
Why?
|
Peroxides | 1 | 2004 | 74 | 0.060 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 2633 | 0.060 |
Why?
|
Pattern Recognition, Visual | 1 | 2010 | 823 | 0.060 |
Why?
|
Regression Analysis | 1 | 2013 | 6452 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2948 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 8925 | 0.060 |
Why?
|
Quinazolines | 1 | 2010 | 1355 | 0.060 |
Why?
|
Reaction Time | 1 | 2010 | 2092 | 0.060 |
Why?
|
Oxygen | 1 | 2015 | 4169 | 0.060 |
Why?
|
Cranial Nerves | 1 | 2003 | 101 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2013 | 2049 | 0.050 |
Why?
|
Palliative Care | 1 | 2018 | 3478 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 5 | 2015 | 35342 | 0.050 |
Why?
|
Sarcoma | 2 | 2012 | 1895 | 0.050 |
Why?
|
Carbon | 1 | 2006 | 686 | 0.050 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8621 | 0.050 |
Why?
|
Cytoskeleton | 1 | 2007 | 1185 | 0.050 |
Why?
|
Photons | 1 | 2006 | 587 | 0.050 |
Why?
|
Prospective Studies | 2 | 2021 | 53187 | 0.050 |
Why?
|
Vitrectomy | 1 | 2005 | 365 | 0.050 |
Why?
|
Piperidines | 1 | 2010 | 1602 | 0.050 |
Why?
|
Cohort Studies | 3 | 2014 | 40450 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2604 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3691 | 0.050 |
Why?
|
Gene Silencing | 1 | 2007 | 1538 | 0.050 |
Why?
|
Eye Diseases | 1 | 2006 | 670 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12242 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2006 | 1269 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2012 | 8829 | 0.040 |
Why?
|
Drug Combinations | 1 | 2004 | 1961 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3502 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2012 | 4465 | 0.040 |
Why?
|
Normal Distribution | 1 | 2019 | 280 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4982 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10392 | 0.040 |
Why?
|
Functional Laterality | 1 | 2004 | 2290 | 0.040 |
Why?
|
Neurofibromatosis 2 | 2 | 2012 | 380 | 0.040 |
Why?
|
Organs at Risk | 1 | 2019 | 346 | 0.040 |
Why?
|
Diabetic Retinopathy | 1 | 2005 | 1205 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2005 | 2107 | 0.030 |
Why?
|
Amygdala | 1 | 2023 | 1305 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2003 | 1379 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2224 | 0.030 |
Why?
|
Body Mass Index | 1 | 2013 | 12695 | 0.030 |
Why?
|
Image Enhancement | 1 | 2006 | 2921 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2012 | 7873 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9963 | 0.030 |
Why?
|
Adenocarcinoma | 2 | 2009 | 6347 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12958 | 0.030 |
Why?
|
Mice, Nude | 2 | 2012 | 3689 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6474 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2502 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2658 | 0.030 |
Why?
|
Recovery of Function | 1 | 2003 | 2924 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11472 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2502 | 0.030 |
Why?
|
Down-Regulation | 2 | 2012 | 3001 | 0.030 |
Why?
|
Eye Burns | 1 | 2013 | 102 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2010 | 798 | 0.020 |
Why?
|
Thrombospondins | 1 | 2012 | 197 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3510 | 0.020 |
Why?
|
Lasers, Solid-State | 1 | 2013 | 169 | 0.020 |
Why?
|
Permeability | 1 | 2012 | 738 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 890 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2010 | 400 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15056 | 0.020 |
Why?
|
Cyclin D | 1 | 2007 | 71 | 0.020 |
Why?
|
Transcription Factors | 1 | 2007 | 12164 | 0.020 |
Why?
|
Disease Progression | 1 | 2004 | 13256 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2012 | 2085 | 0.020 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2008 | 55 | 0.020 |
Why?
|
Signal Transduction | 3 | 2019 | 23387 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6259 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 2007 | 402 | 0.020 |
Why?
|
Mice | 5 | 2013 | 81045 | 0.020 |
Why?
|
Solubility | 1 | 2007 | 1083 | 0.020 |
Why?
|
Blood Vessels | 1 | 2012 | 1124 | 0.020 |
Why?
|
Mutant Proteins | 1 | 2007 | 500 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11363 | 0.020 |
Why?
|
Cyclins | 1 | 2007 | 601 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2013 | 10472 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2012 | 16665 | 0.020 |
Why?
|
Cell Cycle | 1 | 2013 | 2964 | 0.020 |
Why?
|
Cell Polarity | 1 | 2007 | 644 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2938 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3869 | 0.010 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 627 | 0.010 |
Why?
|
Radiotherapy, Conformal | 1 | 2006 | 548 | 0.010 |
Why?
|
Endocytosis | 1 | 2007 | 983 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5872 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2013 | 21821 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 7716 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2007 | 3133 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2007 | 1363 | 0.010 |
Why?
|
Protein Transport | 1 | 2007 | 1988 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2013 | 18006 | 0.010 |
Why?
|
Animals | 5 | 2013 | 168561 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8662 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2007 | 3139 | 0.010 |
Why?
|
Protein Kinases | 1 | 2007 | 1638 | 0.010 |
Why?
|
Sirolimus | 1 | 2007 | 1562 | 0.010 |
Why?
|
Actins | 1 | 2007 | 2120 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12946 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13853 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2007 | 2107 | 0.010 |
Why?
|
Cell Membrane | 1 | 2007 | 3744 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6756 | 0.010 |
Why?
|
Fibroblasts | 1 | 2007 | 4143 | 0.010 |
Why?
|
Quality of Life | 1 | 2018 | 12730 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9715 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23320 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8425 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9410 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11470 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9387 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9735 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 15994 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 5522 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2003 | 3391 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 12071 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 29717 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 20086 | 0.000 |
Why?
|